PDPK1 and renal cell carcinoma: To further delineate the underlying mechanism of CYD-6-17 in suppressing β-catenin expression in RCC cells, we noticed that PDPK1, an AKT activation kinase, was significantly inhibited in CYD-6-17 treatment (Figure 3a).